Department I of Internal Medicine, University of Cologne, Cologne, Germany.
Hepatology. 2012 Jan;55(1):287-97. doi: 10.1002/hep.24625.
Adeno-associated viral vectors (rAAV) are frequently used in gene therapy trials. Although rAAV vectors are of low immunogenicity, humoral as well as T cell responses may be induced. While the former limits vector reapplication, the expansion of cytotoxic T cells correlates with liver inflammation and loss of transduced hepatocytes. Because adaptive immune responses are a consequence of recognition by the innate immune system, we aimed to characterize cell autonomous immune responses elicited by rAAV in primary human hepatocytes and nonparenchymal liver cells. Surprisingly, Kupffer cells, but also liver sinusoidal endothelial cells, mounted responses to rAAV, whereas neither rAAV2 nor rAAV8 were recognized by hepatocytes. Viral capsids were sensed at the cell surface as pathogen-associated molecular patterns by Toll-like receptor 2. In contrast to the Toll-like receptor 9-mediated recognition observed in plasmacytoid dendritic cells, immune recognition of rAAV in primary human liver cells did not induce a type I interferon response, but up-regulated inflammatory cytokines through activation of nuclear factor κB.
Using primary human liver cells, we identified a novel mechanism of rAAV recognition in the liver, demonstrating that alternative means of sensing rAAV particles have evolved. Minimizing this recognition will be key to improving rAAV-mediated gene transfer and reducing side effects in clinical trials due to immune responses against rAAV.
腺相关病毒载体(rAAV)常用于基因治疗试验。尽管 rAAV 载体的免疫原性较低,但仍可能引起体液和 T 细胞反应。虽然前者限制了载体的重复应用,但细胞毒性 T 细胞的扩增与肝炎症和转导的肝细胞丧失有关。由于适应性免疫反应是固有免疫系统识别的结果,我们旨在描述 rAAV 在原代人肝细胞和非实质肝细胞中引发的细胞自主免疫反应。令人惊讶的是,Kupffer 细胞,甚至肝窦内皮细胞,也对 rAAV 产生反应,而肝细胞既不识别 rAAV2 也不识别 rAAV8。病毒衣壳作为病原体相关分子模式被 Toll 样受体 2 识别在细胞表面。与在浆细胞样树突状细胞中观察到的 Toll 样受体 9 介导的识别相反,rAAV 在原代人肝细胞中的免疫识别不会诱导 I 型干扰素反应,而是通过激活核因子 κB 上调炎症细胞因子。
使用原代人肝细胞,我们确定了肝脏中 rAAV 识别的一种新机制,表明已经进化出了识别 rAAV 颗粒的替代方法。最大限度地减少这种识别将是改善 rAAV 介导的基因转移和减少临床试验中因针对 rAAV 的免疫反应引起的副作用的关键。